L'immuno-virothérapie oncolytique, une stratégie émergente de traitement du cancer

Abstract : Oncolytic immuno-virotherapy consists in using replicative viruses to target tumor cells, causes their selective lysis, and thus activates the anti-tumor immune response. This approach, whose concept is relatively old, has become a therapeutic reality since 2015 with the approval of a first product, T-Vec, for the treatment of metastatic melanoma. In this review, we recall the principle of oncolytic therapy and its positive effects on the anti-tumor immune response. The mechanisms involved justify their use in combination with immune checkpoints inhibitors. In parallel with the many preclinical advances, clinical development is very active. There are about fifty trials of phases 1 to 3 in progress in a wide variety of indications, routes of administration and combination. We bet that this multifunctional emergent class, which reprograms the tumor microenvironment (for converting “cold” tumors into “hot” tumors), could quickly become a new valuable weapon in the oncologist’s therapeutic arsenal.
Document type :
Journal articles
Liste complète des métadonnées

https://www.hal.inserm.fr/inserm-02100092
Contributor : Elizabeth Bernardo <>
Submitted on : Monday, April 15, 2019 - 3:24:49 PM
Last modification on : Tuesday, April 16, 2019 - 1:30:15 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

  • HAL Id : inserm-02100092, version 1

Collections

Citation

Jean-François Fonteneau, Eric Quemeneur. L'immuno-virothérapie oncolytique, une stratégie émergente de traitement du cancer. Immunité & Cancer, 2019, 3 (1), Epub ahead of print. ⟨inserm-02100092⟩

Share

Metrics

Record views

48